Singapore – CytoMed Therapeutics, a biotech company based in Singapore, is breaking new ground in the field of cancer treatment with its pioneering cell therapy approach. This innovative technique harnesses the power of the patient’s own cells to fight cancer, offering new hope to late-stage cancer patients with limited treatment options.
CytoMed’s technologies were inspired by the clinical success of chimeric antigen receptor-modified T (CAR-T) cells in treating hematological malignancies and aim to address the clinical limitations and commercial challenges of extrapolating the CAR-T principle into treatments for solid tumors.
CytoMed Therapeutics’ cell therapy approach offers a number of benefits over traditional cancer treatments. First and foremost, it is highly personalized, as it uses the patient’s own cells to fight the cancer. This reduces the risk of rejection and eliminates the need for immunosuppressive drugs. Additionally, cell therapy has been shown to have fewer side effects than chemotherapy and radiation, which can greatly improve patients’ quality of life.
The company’s approach is especially promising for late-stage cancer patients with metastasis who have few treatment options left. CytoMed Therapeutics’ cell therapy has been shown to be effective in attacking cancer cells and improving patients’ outcomes.
“Many late-stage cancer patients have already tried conventional treatments like chemotherapy and radiation, which can be very harsh and have serious side effects,” said Choo. “Our cell therapy offers a more targeted approach that can be effective even when other treatments have failed.”
Despite the lengthy regulatory process and the challenge of making the therapy affordable, CytoMed has already won two first prizes for its innovative approaches. “We faced funding challenges for biotechs, which have dried up in the last year,” Choo adds.
However, with the aging population and rising healthcare costs worldwide, health regulators are looking to hasten the approval of drugs, particularly for unmet, no-option needs with life-threatening implications, even in the US FDA.
Choo emphasizes that patients have a responsibility to educate themselves about their health, particularly as they prepare for old age, as misdiagnosis is common. “International medical tourism means patients can travel to cheaper healthcare countries for treatments which are very expensive in their home countries and not accessible,” he adds.
They recently celebrated the successful completion of its IPO by ringing the Nasdaq closing bell. The IPO marks a significant milestone for CytoMed, providing the company with essential funds to advance its innovative cellular immunotherapies for cancer treatment. The proceeds will support the development of CytoMed’s leading candidate, which utilizes CAR gamma delta T-cells to target various types of cancers, including solid tumors. The IPO also aims to raise CytoMed’s international profile, facilitating potential collaborations and solidifying its position as a key player in the field of cellular immunotherapies.
CytoMed’s cell therapies, including the CTM-N2D and iPSC-γδ gdNKT therapies, exploit the multiple-antigen recognition systems of both natural killer (NK) cells and γδ T cells and may be used to recognize and treat broad range of cancers. The therapies will be manufactured for clinical trials at a cGMP facility in Johor, Malaysia, near Singapore, in accordance with international PIC/S GMP standards.
The Era of the Cell Will Change Our Lives(Opens in a new browser tab)
CytoMed Therapeutics is committed to providing the best possible care to late-stage cancer patients and to advancing the field of cell therapy. To learn more about the company and its groundbreaking approach to cancer treatment, visit their website at www.cytomed.sg.
Discussion about this post